News
AZ builds in China, as J&J ramps up its US investments
AstraZeneca will open its sixth R&D centre in China, while J&J announces four new manufacturing facilities in the US in a major reshoring drive.
News
Fabhalta is first FDA-approved therapy for rare disease C3G
Novartis' oral complement inhibitor Fabhalta has become the first approved treatment for rare kidney disease C3G as it chases a $3bn sales target.
News
J&J adds to IL-23 options in Crohn's after FDA approval
J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.
News
Alnylam joins three-way contest in ATTR cardiomyopathy
Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
